Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 292,891	$ 519,446
Available for sale securities	8,112	50,875
Accrued interest receivable	75	348
Accounts receivable, net of allowances of approximately $23.4 million and $17.7 million at June 30, 2013 and December 31, 2012, respectively	90,333	85,893
Inventory	86,750	76,355
Deferred tax assets	13,881	13,881
Prepaid expenses and other current assets	10,598	9,577
Total current assets	502,640	756,375
Fixed assets, net	30,053	16,100
Intangible assets, net	462,486	119,576
Goodwill	135,627	14,671
Restricted cash	1,558	1,571
Deferred tax assets, net	0	46,625
Other assets	17,559	17,264
Total assets	1,149,923	972,182
Current liabilities:
Accounts payable	5,067	25,378
Accrued expenses	113,235	107,453
Deferred revenue	2,319	2,375
Total current liabilities	120,621	135,206
Contingent purchase price	100,524	18,971
Deferred tax liabilities	34,504	0
Convertible senior notes (due 2017)	231,025	226,109
Other liabilities	5,815	5,674
Total liabilities	492,489	385,960
Stockholders' equity:
Preferred stock, $1.00 par value per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value per share, 125,000,000 shares authorized; 58,797,762 issued and 56,604,780 outstanding at June 30, 2013 and 56,153,140 issued and 53,960,158 outstanding at December 31, 2012, respectively	58	56
Additional paid-in capital	763,127	697,427
Treasury stock, at cost; 2,192,982 shares at June 30, 2013 and December 31, 2012, respectively	(50,000)	(50,000)
Accumulated deficit	(53,890)	(60,411)
Accumulated other comprehensive loss	(1,684)	(766)
Total The Medicines Company stockholders' equity	657,611	586,306
Non-controlling interest in joint venture	(177)	(84)
Total stockholders' equity	657,434	586,222
Total liabilities and stockholders' equity	$ 1,149,923	$ 972,182